Sumitomo Pharma America, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2014-04-03
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT01082146
- Locations
- 🇺🇸
Covance Global Clinical Research Unit Inc., Madison, Wisconsin, United States
Lithium Drug-Drug Interaction Study With Lurasidone HCl
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2011-09-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01074073
- Locations
- 🇺🇸
CCT/Parexel, Culver City, California, United States
Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl
- Conditions
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2011-09-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT01074632
- Locations
- 🇺🇸
Clinical Research Institute, Wichita, Kansas, United States
🇺🇸California Clinical Trials, Glendale, California, United States
A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
- First Posted Date
- 2010-02-11
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 824
- Registration Number
- NCT01067105
- Locations
- 🇺🇸
Kerrville Research Associates, Kerrville, Texas, United States
🇺🇸Asthma, Nasal Disease, and Allergy Research Center of New England, Providence, Rhode Island, United States
🇺🇸Allergy and Asthma Specialists Group, Huntington Beach, California, United States
Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults
- First Posted Date
- 2010-01-05
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01042106
- Locations
- 🇺🇸
Cetero Research, San Antonio, Texas, United States
Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis
- Conditions
- Interventions
- First Posted Date
- 2009-12-17
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 310
- Registration Number
- NCT01033825
- Locations
- 🇺🇸
Clinical Research Institute, Minneappolis, Minnesota, United States
🇺🇸Clinical Research Atlanta, Stockbridge, Georgia, United States
🇺🇸Central Texas Health Research, New Braunfels, Texas, United States
Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older
- Conditions
- Interventions
- First Posted Date
- 2009-11-10
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 671
- Registration Number
- NCT01010971
- Locations
- 🇺🇸
Sinus Clinical Research LLC, Austin, Texas, United States
🇺🇸Southwest Allergy and Asthma Research Center, Pa, San Antonio, Texas, United States
🇺🇸Sylvana Research, San Antonio, Texas, United States
A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
- Conditions
- Interventions
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 1110
- Registration Number
- NCT00953147
- Locations
- 🇺🇸
Pharmaceutical Research and Consulting, Dallas, Texas, United States
🇺🇸California Allergy and Asthma Medical Group, Los Angeles, California, United States
🇺🇸CHOC PSF, AMC, Division of Allergy Asthma & Immunology, Orange, California, United States
Eslicarbazepine Acetate Monotherapy Long Term Study
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 274
- Registration Number
- NCT00910247
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Texas Neurology, PA, Dallas, Texas, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 841
- Registration Number
- NCT00909779
- Locations
- 🇺🇸
C.A.R.E. Clinical Research, St. Louis, Missouri, United States
🇺🇸Neem Research Group, Inc., Columbia, South Carolina, United States
🇺🇸DCT, Sugar Land, Texas, United States